Millennial Pharmaceuticals

Millennium Pharmaceuticals is a leading biopharmaceutical company focused on oncology and inflammation, now operating as a wholly owned subsidiary of Takeda Pharmaceutical Company. The company rose to prominence by leveraging genomics-based drug discovery to develop breakthrough therapies, most notably the first-in-class proteasome inhibitor Velcade (bortezomib) for multiple myeloma. Following its acquisition by Takeda in 2008, it became the center of Takeda's global oncology business unit. Millennium continues to manage a robust pipeline of targeted therapies, including oral proteasome inhibitors and antibody-drug conjugates, while supporting a commercial portfolio that includes Entyvio (vedolizumab) and Adcetris (brentuximab vedotin).